Kabra Drugs share news and announcements
BSE: 524322Pharmaceuticals & BiotechnologySmall Cap
Last close ₹16.15down ₹0.49 (2.94%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹16.64.
52-week range of traded prices to 23 Oct 2026
₹15.50Low, 23 Oct 2026₹35.52High, 11 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹38 Cr3,225th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 12 Aug 2026
- 5.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- 28.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- 28.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day.
- 58,004
Kabra Drugs routine notices
80 filed, newest first. Page 2 of 2.
May 2022
Apr 2022
Mar 2022
Jan 2022
Dec 2021
Oct 2021
Sep 2021
Jul 2021
Jun 2021
Apr 2021
Mar 2021
Dec 2020
Dec 2019
Oct 2019
Jun 2019
Apr 2019
Jan 2019
Nov 2018
May 2018
Feb 2018
1 Feb · Routine
May 2017
Feb 2017
4 Feb · Routine
Nov 2016
Sep 2016
Oct 2015
30 Oct · Routine
As per the Company's Code of Conduct for Prevention of insider Trading read with Securities Exchange Board of India (Prohibition of Insider Trading) ....
Aug 2015
6 Aug · Routine
May 2015
27 May · Routine
As per the Company’s Code of Conduct for Prevention of Insider Trading read with Securities Exchange Board of India (Prohibition of Insider Trading) ....